VYNE Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing differentiated therapies for the treatment of immuno-inflammatory conditions. The Company’s lead product candidate, FMX114, which is in Phase IIa, is being evaluated for the potential treatment of mild-to-moderate atopic dermatitis (AD). The Company is also engaged in the pre-clinical stages of developing products containing Bromodomain and Extra-Terminal Domain (BET) inhibitor compounds. Its initial BET inhibitor candidate in development is VYN201, a locally administered pan-BET inhibitor, which the Company is exploring in various immuno-inflammatory diseases, including skin diseases. Its VYN202 is a pan-BD BET inhibitor that is being developed to address diseases involving multiple, diverse inflammation. In addition, the Company continues to explore opportunistic transactions that enhance its pipeline portfolio, as well as support its operations and fund its future growth.